CANF (Can Fite Biopharma) Short Percentage of Float


CANF Can Fite Biopharma Ltd CANF
60 GF Score
Price $2.99
GF Value $5.98
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Can Fite Biopharma Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CANF vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Can Fite Biopharma's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Can Fite Biopharma Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Can Fite Biopharma's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Can Fite Biopharma's Short Percentage of Float falls into.


CANF
60GF Score
Can Fite Biopharma Ltd CANF
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Can Fite Biopharma (CANF) Overvalued in 2026?

Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued. The current stock price of $2.99 is trading 50% below its estimated GF Value™ of $5.98. GuruFocus considers Can Fite Biopharma to be Significantly Overvalued.

Key valuation signals for CANF:

  • Short Percentage of Float:
  • GF Value™: $5.98 vs. price of $2.99 (50% below fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Can Fite Biopharma Business Description

Other Exchanges CANF:Israel
Address 26 Ben Gurion Street, Ramat Gan, ISR, 5257346
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
60GF Score

Get the complete analysis for CANF

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.99
Price
$5.98
GF Value